AGIO Agios Pharmaceuticals Inc

nothing landing today on the FDA clock and I am fine with that the next 7 days are the actual trade though Friday Oct 30 INO 3107 PDUFA in recurrent respiratory papillomatosis Sunday Nov 1 $AGIO mitapivat PDUFA in sickle cell disease, so Friday is the practical window again and Palvella just set a new clock this morning, QTORIN rapamycin Priority Review with a Feb 28 2027 decision date, first potential therapy for microcystic lymphatic malformations two dates in the next 7 days, one fresh clock behind them, that is the week imo

$AGIO wholesome swing to RED , days before an FDA (. Ya right, a Sunday ) news Guess the street knows the lies of Fouse and Goff pretty well at this point . !!! No lies over at $ALNY !!!! Yvonne , knows big pharma and is a straight shooter

$AGIO How analysts show the world they are hardly working: Agios Pharmaceuticals, Inc. AGIO.O: Leerink Partners cuts PT to $72 from $73

$AGIO you are another sucker of the AGIOS camp of imbeciles….you’ll see , 8 years of nothing but salaries for Previously laid off biotech misfits ! Truth always hurts and YOU : ??LMAO

$AGIO not a bright choice …plagued with liars and executives that sell the stock, never buy it No real innovators left here, just money people sucking on thr tit , a previous scientist , Bowden’s discoveries . !!! Goof ball Goff took over after useless Jackie Fouse and LIAR SCHENKIEN . There you have it , they were inadequate, return the goods , credit your credit card, for as Kastanza said :

TRADE ALERT $AGIO setup is catalyst runup. Nov 1 PDUFA for mitapivat in sickle cell is 11 days out, Priority Review on the accelerated path, and Friday is the practical window since Nov 1 is a Sunday. RISE UP hit 40.6 percent hemoglobin response vs 2.9 on placebo and the drug is already approved in thalassemia entry zone $36.50 to $37.30, trading $37.21 today after Monday broke out to a $34.90 close stop on a close under $34.85 Targets: $38.30, then $40.50 it sat between 30 and 32 for weeks, then Monday jumped 11 percent on 2 million shares and Tuesday held every bit of it above 35. today it pushed to $37.46, above the 50 day at 33.20 and the 200 day at 31.36. the runup is doing the work before the binary imo, like it is supposed to. score 76. size it like a binary because it is one

$AGIO 🚨 TESTING INSTITUTIONAL BUY ZONE | SICKLE CELL PDUFA FEB 1 🚨$AGIO is consolidating inside its $30.80 – $32.00 Institutional Buy Zone on the 8H chart! Lower trendline support holding strong ahead of Nov 5 earnings & Feb 1 PDUFA. 📊 CHART ZONES ($AGIO, 8H): • Smart Money Sell: $42.50 – $45.00 • Institutional Sell: $37.50 – $39.50 • Reclaim Target: $34.00 – $35.50 • Institutional Buy: $30.80 – $32.00 (CURRENT LOAD) • Smart Money Buy: $29.50 – $30.50 🎯 KEY LEVELS: 🐂 Bull Trigger: Defend $30.00 & reclaim $34.00 to target $37.50+. 🐻 Bear Trigger: 8H close below $29.50. BIAS: Tactical Dip-Buy off $30–$32 Trendline Support 📊📈#hovdid

$AGIO Not a good look. She knew. I don’t care what kind of plan is in place. Guaranteed that’s the last sale for a long time.

$AGIO yeah not great news for patients or the company. Not catastrophic either. Less than 1k shares traded thus far

Sunday date, Friday decision in practice ngl $AGIO Nov 1 PDUFA is 12 days out, Priority Review for mitapivat in sickle cell, accelerated approval path. RISE UP had hemoglobin response at 40.6 percent vs 2.9 on placebo, it is already approved in thalassemia, and it is trading at 36.37 today after closing Monday at 34.90. quiet for the next name on the FDA clock imo